PwPepwise

Amycretin

Weight Loss

Oral GLP-1 / amylin dual agonist

Amycretin is a first-in-class, single-molecule drug that simultaneously activates two complementary appetite-regulating pathways in the body: the…

§Dosing at a glance

2 protocols · from the research
What it's forDoseHow oftenHowFor how long
under the skin (SC) injection — once weekly0.3 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.36 wks
Oral administration — once daily1 mgOnce dailyOralTaken by mouth.12 wks

Approximate values pulled from the research — double-check before dosing.

§01Summary

Amycretin is a first-in-class, single-molecule drug that simultaneously activates two complementary appetite-regulating pathways in the body: the GLP-1 receptor, which is the same target engaged by widely-used weight-loss medications like semaglutide, and the amylin receptor, which signals satiety through a different region of the brain. By engaging both systems within one molecule, amycretin may produce stronger and more sustained reductions in hunger and body weight than either mechanism alone.1,2

In early-phase human trials, once-weekly subcutaneous injections of amycretin produced dose-dependent weight loss of up to 24.3% over 36 weeks at the highest tested dose,2 while an oral formulation showed up to approximately 13.1% weight loss over 12 weeks.8 These results have positioned amycretin as one of the more promising next-generation obesity therapies currently in development. Side effects reported in clinical studies were primarily gastrointestinal — such as nausea and vomiting — and were mostly mild to moderate in severity, consistent with other medications in this drug class.1,2 Amycretin is currently in active clinical development by Novo Nordisk, with human efficacy and safety data continuing to emerge from ongoing studies.1,2

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Amycretin is a unimolecular co-agonist engineered to simultaneously activate two distinct G protein-coupled receptor systems: the glucagon-like peptide-1 receptor (GLP-1R) and the amylin receptor complex (AMY receptor, comprising calcitonin receptor subunits paired with receptor activity-modifying proteins).1,4 This dual pharmacology is achieved within a single synthetic peptide scaffold, distinguishing amycretin from combination therapies or separate co-administration of individual agonists. Cell-based receptor activation studies have confirmed that amycretin engages GLP-1 receptors, amylin receptors, and calcitonin receptors in human, mouse, and rat systems.4

GLP-1R agonism drives several complementary metabolic effects: enhanced glucose-dependent insulin secretion from pancreatic beta cells, suppression of glucagon release, slowed gastric emptying, and centrally mediated appetite suppression via hypothalamic and brainstem GLP-1R circuits.8 Amylin receptor agonism operates through a mechanistically distinct but complementary pathway, principally targeting the area postrema in the hindbrain — a circumventricular organ outside the blood-brain barrier — to reinforce satiety signaling and suppress food intake independently of GLP-1R.4,8 Amycretin has been shown to penetrate the CNS and reach brain regions governing food intake regulation in preclinical models, providing mechanistic grounding for its appetite-suppressive efficacy.4

The combination of these two receptor engagement pathways appears to produce additive or synergistic reductions in energy intake. In diet-induced obese rats, amycretin reduced total energy intake by 47% and body weight by 18% over 21 days while maintaining energy expenditure — a pattern suggesting the weight loss was driven primarily by reduced caloric consumption rather than metabolic suppression.4 Improvements in insulin sensitivity, as measured by hyperinsulinemic euglycemic clamp, and reductions in histological markers of metabolic-dysfunction-associated steatotic liver disease (primarily through steatosis reduction) were also observed in this preclinical model.4

Pharmacokineticaly, oral amycretin demonstrates dose-proportional increases in AUC and Cmax across single and multiple ascending dose cohorts, consistent with linear pharmacokinetics.1,3 Dose-proportional pharmacokinetics were similarly observed with subcutaneous formulations, supporting predictable exposure-response relationships suitable for dose optimization in later-phase trials.3 The once-weekly subcutaneous dosing interval is consistent with the extended half-life achievable through peptide engineering strategies typical of this drug class. The oral bioavailability of a peptide of this complexity is a technically notable feature, enabled by formulation strategies that protect the molecule from gastrointestinal proteolysis — an area that continues to be characterized in ongoing clinical studies.1,8

§04Evidence & efficacy

Evidence base
21Studies
8Human
0Animal

Amycretin has demonstrated statistically significant, dose-dependent body weight reductions in Phase 1b/2a randomized controlled studies of subcutaneous administration. At the highest tested dose (60 mg SC once weekly over 36 weeks), mean body weight decreased by 24.3% versus −1.1% for placebo (p<0.0001).2,3 At 20 mg over 36 weeks, mean reduction was 22.0% versus +1.9% for placebo; at 5 mg over 28 weeks, 16.2% versus +2.3%; and at 1.25 mg over 20 weeks, 9.7% versus +2.0%, all statistically significant.2,3 These magnitudes appear to exceed or rival efficacy benchmarks reported for currently approved GLP-1 receptor agonists such as semaglutide (~15–17% at 68 weeks) and are comparable to or may surpass results reported for tirzepatide.2,3

With oral administration, exploratory pharmacodynamic data over 12 weeks in Part C/D of the Phase 1 trial support meaningful body weight reductions, with up to approximately 13.1% loss reported in a review of available clinical data.8 Pharmacokinetics were consistent with dose proportionality across all oral treatment groups, suggesting predictable exposure-response relationships relevant to dose optimization.1

In DIO rat models, amycretin produced an 18% reduction in body weight and a 47% reduction in total energy intake over 21 days compared to vehicle, alongside improvements in insulin sensitivity and markers of metabolic-dysfunction-associated steatotic liver disease.4 CNS penetration into food-intake-regulating brain regions was also demonstrated, supporting the proposed dual hindbrain satiety mechanism.4

Amycretin's effects on glycemic control, including fasting plasma glucose reductions, have been observed as exploratory endpoints in early human studies1 and in patients with overweight and obesity with type 2 diabetes,5,6 with the full characterization of glycemic efficacy actively developing through later-phase trials.

§05Safety

Across both oral and subcutaneous clinical studies, amycretin has demonstrated a tolerability profile consistent with the GLP-1 receptor agonist drug class.1,2 In the Phase 1 oral study, 364 treatment-emergent adverse events (TEAEs) were reported among 89 of 144 participants (62%), all of which were mild or moderate in severity.1 Gastrointestinal events were the most common category, accounting for 49% of all adverse events (180 of 364) and occurring in 81% of participants who reported any adverse event.1 No deaths and no severe adverse events were reported in this study.1

In the Phase 1b/2a subcutaneous study, gastrointestinal TEAEs were similarly the most frequently reported events, predominantly mild to moderate in severity and largely self-resolving.2,3 A notable proportion of participants withdrew from the subcutaneous study, though a large share of discontinuations were attributed to reasons unrelated to adverse events.2 Adverse event frequency appeared to increase in a dose-dependent manner with oral dosing.1

Preclinical data in diet-induced obese (DIO) rats showed that amycretin maintained energy expenditure while reducing food intake, which is generally regarded as a favorable metabolic safety signal.4 No unexpected or novel safety signals have been identified in published studies to date.2,3,8

Long-term safety data beyond 36 weeks in humans are actively being generated through ongoing clinical development, and the safety profile in broader patient populations — including those with type 2 diabetes, cardiovascular disease, or renal impairment — remains an area of active investigation.1,2

§06History

Amycretin was conceived and developed by Novo Nordisk as a next-generation approach to obesity and metabolic disease pharmacotherapy. The scientific rationale draws on decades of research into two distinct hormonal satiety systems: GLP-1, whose receptor agonists have been in clinical development since the early 2000s (leading to approvals of exenatide, liraglutide, and eventually semaglutide), and amylin, a pancreatic co-secreted peptide whose analog pramlintide was approved for diabetes management in 2005 but required injection and offered modest weight loss as a secondary benefit.

The key insight driving amycretin's development was that combining GLP-1R agonism and amylin receptor agonism within a single unimolecular entity — rather than co-administering two separate agents — could simplify treatment while potentially achieving additive or synergistic efficacy through complementary satiety circuits.1,2 Preclinical mechanistic work, including CNS penetration studies and receptor activation profiling across human and rodent systems, established the biological plausibility of this dual-agonist design.4

Amycretin entered first-in-human clinical testing, with results from Phase 1 oral and Phase 1b/2a subcutaneous studies published in The Lancet in June 2025.1,2 These publications represented milestone findings, demonstrating both the tolerability of the oral formulation and the remarkable magnitude of weight loss with subcutaneous dosing — up to 24.3% at 36 weeks.2 Findings were simultaneously presented at the American Diabetes Association Scientific Sessions in 2025.3 As of 2025–2026, amycretin is in active clinical development, with the evidence base expanding through additional registered trials.1,2,8

§07References